The comprehensive industry research on Multiple Endocrine Neoplasia Treatment Market published by Data Bridge Market research which includes growth analysis,
Author summary Why was this study done? Compared to Alzheimer’s disease (AD), dementia with Lewy bodies (DLBs) is associated with accelerated cognitive decline, lower quality of life, higher caregiver burden, shorter lifespan, and higher costs of care, as well as increased rates of admission to general hospitals and residential care and longer length of stay. Although there are no disease-modifying medications for DLB, there is evidence suggesting that acetylcholinesterase inhibitors (AChEIs) and glutamate N-methyl-D-aspartate receptor antagonists (specifically, memantine) are efficacious in DLB, though an impact on mortality is not clear. Distinct evidence on any survival benefit of AChEIs and memantine in DLB needs to be explored specifically, as DLB is pathologically and clinically different from AD and other forms of dementia. What did the researchers do and find? We identified 592 patients with DLB, including 219 who never took AChEIs or memantine, 100 who took AChEIs